Our mission is to shape the future of medicine by developing safe and efficacious drugs, and powerful research and diagnostic tools, based on our proprietary Affimer® platform. Avacta is developing novel cancer immunotherapies combining its two proprietary platforms - Affimer® biotherapeutics and tumour targeted chemotherapy. With this approach, the Company aims to address the lack of a durable response to current immunother...
Our mission is to shape the future of medicine by developing safe and efficacious drugs, and powerful research and diagnostic tools, based on our proprietary Affimer® platform. Avacta is developing novel cancer immunotherapies combining its two proprietary platforms - Affimer® biotherapeutics and tumour targeted chemotherapy. With this approach, the Company aims to address the lack of a durable response to current immunotherapies experienced by most patients. Avacta's proprietary targeted chemotherapy platform, releases active drug only in the tumour, thereby limiting systemic exposure and improving the overall safety.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.